JHVEPhoto One of the biggest mistakes for investors is to get caught up in market exuberance on a particular stock. This appears to have been the case with a number of big pharmaceutical names in 2022, as investors prized their cash rich and inflation resistant nature, and all the while bidding up their prices. This includes Amgen (NASDAQ: AMGN ), whose share price traded as high as $296 in recent months, before crashing down to its present level, as shown below. In this article, I highlight why this crash presents a good opportunity for value investors to layer into this moat-worthy stock. AMGN Stock (Seeking Alpha) Why AMGN? Amgen is one of the largest global biotech companies, after having been one of the pioneers in this space since 1980. It’s also a member of the prestigious Dow 30 companies, with expertise in inflammatory diseases, oncology, and biosimilars. As shown below, AMGN has demonstrated a rather strong and steady revenue growth trajectory over the past 10 years. YCharts AMGN recently closed a fourth quarter that looked lackluster on the surface. This includes total revenue growth of just 2%. This was driven by 9% product volume growth that was partially offset […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
